Molecure Valuation
Is 1B1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1B1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1B1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1B1's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1B1?
Key metric: As 1B1 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 1B1's PB Ratio? | |
|---|---|
| PB Ratio | 2.1x |
| Book | zł80.09m |
| Market Cap | zł166.68m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 94.4x |
| Enterprise Value/EBITDA | -4.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 1B1's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
SBX SynBiotic | 1.8x | 107.0% | €27.9m |
HIGH Cantourage Group | 1.3x | 112.7% | €57.6m |
APPH Apontis Pharma | 2.7x | 78.1% | €82.6m |
B8FK Biofrontera | 0.9x | n/a | €16.1m |
1B1 Molecure | 2.1x | 1.4% | €166.7m |
Price-To-Book vs Peers: 1B1 is expensive based on its Price-To-Book Ratio (2.1x) compared to the peer average (1.7x).
Price to Book Ratio vs Industry
How does 1B1's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 11 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 1B1 is good value based on its Price-To-Book Ratio (2.1x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 1B1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 1B1's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €2.24 | €4.24 +89.3% | 9.6% | €4.65 | €3.83 | n/a | 2 |
| Nov ’25 | €2.23 | €6.47 +190.7% | 7.9% | €6.98 | €5.96 | n/a | 2 |
| Oct ’25 | €3.03 | €6.48 +114.3% | 7.9% | €6.99 | €5.97 | n/a | 2 |
| Sep ’25 | €3.44 | €7.01 +104.0% | 14.1% | €8.00 | €6.02 | n/a | 2 |
| Aug ’25 | €3.40 | €7.01 +106.1% | 14.1% | €8.00 | €6.02 | n/a | 2 |
| Jul ’25 | €3.11 | €7.01 +125.4% | 14.1% | €8.00 | €6.02 | n/a | 2 |
| Jun ’25 | €3.38 | €7.01 +107.7% | 14.1% | €8.00 | €6.02 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.55
7D
-4.0%
1Y
78.7%
Collegium Pharmaceutical
US$1.0b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.60
7D
5.7%
1Y
27.6%
Pharming Group
€491.5m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.70
7D
-0.7%
1Y
-34.1%